This is a demo store. No orders will be fulfilled.

Blosozumab (anti-SOST), 硬骨蛋白抑制剂的抑制剂

    应用:
  • Animal Model
  • ELISA
  • Flow Cytometry
  • Functional Assay
  • 宿主种属: 人(Human)
  • 种属反应性: 人(Human), 大鼠(Rat), 食蟹猴(Cynomolgus monkey)
  • 亚型: Human IgG4SP
  • 偶联: Unconjugated
有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭
货号 (SKU) 包装规格 是否现货 价格 数量
Ab170542-100μg
100μg 现货 Stock Image
Ab170542-1mg
1mg 现货 Stock Image
Ab170542-5mg
5mg 现货 Stock Image
Ab170542-10mg
10mg 期货 Stock Image

基本信息

产品名称 Blosozumab (anti-SOST), 硬骨蛋白抑制剂的抑制剂
别名 布洛索单抗(抗社会变革病毒)
英文别名 Blosozumab | BEER antibody | CDD antibody | Cortical hyperostosis with syndactyly antibody | Sclerosteosis antibody | Sclerostin antibody | Sost antibody | SOST_HUMAN antibody | SOST1 antibody | UNQ2976/PRO7455/PRO7476 antibody | VBCH antibody | sclerosti
规格或纯度 无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属 人(Human)
特异性 SOST
应用 ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR)
种属反应性 人(Human),大鼠(Rat),食蟹猴(Cynomolgus monkey)
偶联 Unconjugated
作用类型 抑制剂
作用机制 硬骨蛋白抑制剂的抑制剂

产品属性

抗体类型 Primary antibody
克隆类型 重组抗体
Format Whole IgG
亚型 Human IgG4SP
轻链亚型 kappa
SDS-PAGE 26.6 kDa (Light Chain) & 53.9 kDa (Heavy Chain), under reducing conditions; 183.0 kDa, under non-reducing conditions.
纯化方法 Protein A purified
纯度 >95%
来源 CHO supernatant
物理外观 Liquid
储存缓冲液 Supplied as a 0.22 μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂 No
浓度 见COA
储存温度 -80℃储存,避免反复冻融
运输条件 超低温冰袋运输
稳定性与储存 在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息 1132758-87-2
分子类型 抗体

关联靶点(人)

SOST Tclin 硬化蛋白(Sclerostin) (0 活性数据)
活性类型 活性值-log(M) 作用机制 期刊 参考文献(PubMed IDs)

作用机制

作用机制 Action Type target ID Target Name Target Type Target Organism Binding Site Name 参考文献

图片

Blosozumab (anti-SOST) (Ab170542) - SEC
The purity of Blosozumab (anti-SOST) (Ab170542) is more than 95% verified by HPLC.

质检证书(CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA,每批产品都进行了严格的验证,您可放心使用!

找到5个结果

批号(Lot Number) 证书类型 货号
ZJ23F1202001 分析证书 Ab170542
ZJ23F1202002 分析证书 Ab170542
ZJ24F1012804 分析证书 Ab170542
ZJ24F1012803 分析证书 Ab170542
ZJ24F1012802 分析证书 Ab170542

引用文献

1. Brunkow, M E ME and 17 more authors..  (2001)  Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein..  American journal of human genetics,  [PMID:11179006]
2. Balemans, W W and 20 more authors..  (2001)  Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)..  Human molecular genetics,  (1): [PMID:11181578]
3. Balemans, W W and 14 more authors..  (2002)  Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease..  Journal of medical genetics,  [PMID:11836356]
4. Semënov, Mikhail M, Tamai, Keiko K and He, Xi X..  (2005)  SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor..  The Journal of biological chemistry,  (22): [PMID:15908424]
5. Veverka, Vaclav V and 15 more authors..  (2009)  Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation..  The Journal of biological chemistry,  (17): [PMID:19208630]
6. Didangelos, Athanasios A and 5 more authors..  (2010)  Proteomics characterization of extracellular space components in the human aorta..  Molecular & cellular proteomics : MCP,  [PMID:20551380]
7. Piters, Elke E and 12 more authors..  (2010)  First missense mutation in the SOST gene causing sclerosteosis by loss of sclerostin function..  Human mutation,  [PMID:20583295]
8. Kim, Su Jin SJ and 16 more authors..  (2011)  Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia..  Human genetics,  [PMID:21221996]
9. Leupin, Olivier O and 21 more authors..  (2011)  Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function..  The Journal of biological chemistry,  (3): [PMID:21471202]
10. Langdahl, Bente L BL and 21 more authors..  (2017)  Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial..  Lancet (London, England),  (30): [PMID:28755782]

溶液计算器